Testing a new cancer drug for advanced solid tumors with a specific genetic mutation

Plain-English translation of NCT07349537 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new medication called to see if it can help treat advanced cancers that have a specific genetic mutation (KRAS G12V). Researchers want to find the right dose of the medication and understand how well it works, either by itself or combined with other treatments. This is one of the first human studies of this new drug.

Most people with these types of advanced cancers have limited treatment options after standard therapies stop working. This medication targets the specific genetic change that drives these cancers, which may offer a new hope for patients who need more options.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with an advanced cancer that has the KRAS G12V genetic mutation
your cancer has grown or returned despite previous standard treatments
you are in good enough health to tolerate a clinical trial (measured by your doctor's assessment)
you can take medications by mouth and your organs are functioning well enough

You likely don't qualify if…

you have a brain tumor as your primary cancer
you have previously taken a KRAS-targeted therapy or similar genetic mutation-blocking drug
you have a condition that would prevent you from taking or absorbing oral medications
you had major surgery within the past 4 weeks
you are unable or unwilling to attend required study visits and procedures

What participation looks like

You would visit the study center regularly to receive the medication and have your health monitored through blood tests, imaging scans, and check-ins with your doctor. The trial has different treatment options — some participants take the new medication alone, while others receive it combined with one of two other drugs. Your doctor will work with you to find the right dose and monitor how your body responds to the treatment.

AI-generated summary from trial data · Jul 15, 2026 · Not medical advice

Trial locations(9 sites)

United States

Yale Cancer Center, New Haven, Connecticut

Johns Hopkins, Baltimore, Maryland

Dana-Farber Cancer Institute, Boston, Massachusetts

START Midwest, Grand Rapids, Michigan

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York